Piper Sandler & Co’s Standard BioTools LAB Stock Holding History

Piper Sandler & Co’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,000	Closed	-$132K	–	135
2014 Q1	$132K	Buy	+3,000	New	+$132K	0.11%	85

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Piper Sandler & Co's LAB Position: Q2 2014 in Review

Piper Sandler & Co sold out of Standard BioTools (LAB) in Q2 2014, closing a stake of 3,000 shares — an estimated $132K sold.

Piper Sandler & Co first reported a position in LAB in Q1 2014 and held it in 1 quarter. The position peaked at $132K in Q1 2014. 104 funds tracked by Wall St. Rank hold LAB as of Q2 2014.

Piper Sandler & Co reported no remaining Standard BioTools position as of Q2 2014 after selling out during the quarter.
Piper Sandler & Co sold 3,000 Standard BioTools shares in Q2 2014, an estimated $132K.
Piper Sandler & Co first reported a position in Standard BioTools in Q1 2014 and held it in 1 quarter.
Piper Sandler & Co's Standard BioTools position peaked at $132K in Q1 2014.
104 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2014.

Based on Piper Sandler & Co's 13F filing for Q2 2014, filed 14 Aug 2014.